A detailed history of Portside Wealth Group, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Portside Wealth Group, LLC holds 1,547 shares of REGN stock, worth $1.07 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
1,547
Previous 1,322 17.02%
Holding current value
$1.07 Million
Previous $694 Million 25.33%
% of portfolio
0.12%
Previous 0.1%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

BUY
$534.91 - $598.71 $120,354 - $134,709
225 Added 17.02%
1,547 $870 Million
Q2 2025

Aug 11, 2025

BUY
$483.07 - $625.6 $100,478 - $130,124
208 Added 18.67%
1,322 $694 Million
Q1 2025

Apr 14, 2025

BUY
$634.14 - $744.83 $214,339 - $251,752
338 Added 43.56%
1,114 $707 Million
Q1 2025

Apr 10, 2025

BUY
$634.14 - $744.83 $34,877 - $40,965
55 Added 7.63%
776 $553 Million
Q4 2024

Jan 15, 2025

SELL
$701.85 - $1046.91 $2,105 - $3,140
-3 Reduced 0.41%
721 $758 Million
Q3 2024

Oct 31, 2024

BUY
$1024.09 - $1201.76 $95,240 - $111,763
93 Added 14.74%
724 $761 Million
Q2 2024

Jul 18, 2024

BUY
$883.2 - $1071.19 $28,262 - $34,278
32 Added 5.34%
631 $663 Million
Q1 2024

Apr 17, 2024

BUY
$902.69 - $993.35 $47,842 - $52,647
53 Added 9.71%
599 $577 Million
Q4 2023

Jan 16, 2024

BUY
$775.18 - $881.7 $44,960 - $51,138
58 Added 11.89%
546 $480 Million
Q3 2023

Oct 27, 2023

BUY
$692.45 - $844.37 $62,320 - $75,993
90 Added 22.61%
488 $401 Million
Q2 2023

Sep 01, 2023

SELL
$700.03 - $830.35 $11.7 Million - $13.9 Million
-16,716 Reduced 97.67%
398 $286 Million
Q2 2023

Aug 01, 2023

BUY
$700.03 - $830.35 $12 Million - $14.2 Million
17,114 New
17,114 $12.3 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $74.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Portside Wealth Group, LLC Portfolio

Follow Portside Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Portside Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Portside Wealth Group, LLC with notifications on news.